ProCE Banner Activity

FELIX: Phase Ib/II Study of Obecabtagene Autoleucel in Adults With Relapsed/Refractory B-Cell ALL

Conference Coverage
Slideset

In this analysis of the phase Ib/II FELIX study of tumor burden–guided split dosing with obecabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia, 40% of responders remained in remission with no subsequent therapy after nearly 2 years of follow-up.

Released: June 06, 2024

Expiration: June 05, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from GSK, Lilly, Novartis Pharmaceuticals Corporation, and Sanofi.

GSK

Lilly

Novartis Pharmaceuticals Corporation

Sanofi